![]() |
We are a European specialty pharmaceutical group dedicated to partnering, discovering and developing innovative, value-added products that improve quality of life and help people to enjoy longer, healthier and more productive lives. Our success will benefit not only the patients whose needs we meet but all our stakeholders whom we serve - our customers, our shareholders, our employees and their families. Latest News
Milan, 3 February 2010
Recordati: silodosin (Urorec®/Silodix™) approved by the European Commission for the treatment of the signs and symptoms of BPH Milan, 20 November 2009 Recordati: EMEA/CHMP adopts a positive opinion for silodosin (brands Urorec® and Silodyx™) More Latest News Stay Informed?Keep up to date with the latest information by registering for our alert service. |
![]() |
Share PriceAnnual Report![]() [PDF] ![]() (External) | |
![]() | ||||